Spectral is seeking U.S. FDA approval for its lead product, Toraymyxin, a treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, the most important microbial trigger for sepsis, from the bloodstream. Directed by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared, CE marked diagnostic for the detection of endotoxin, Spectral’s EUPHRATES trial is the world’s first theranostics trial in the area of sepsis.

Toraymyxin was approved for therapeutic use in Japan in 1994 and Europe in 2002 and has been used safely and effectively in more than 340,000 patients worldwide. In March 2009 and November 2010 respectively, Spectral obtained the exclusive development and commercial rights in the U.S. and Canada for Toraymyxin.

More than 1.7 million patients in the United States are diagnosed with sepsis each year. Approximately one third of these patients progress to severe sepsis and septic shock, representing a significant unmet need and an approximately $1.5 billion market opportunity for Spectral.

Spectral continues to provide high quality reagents in which royalty revenue is earned from license for the Company’s proprietary Troponin I and other reagent technologies. License arrangements are held with industry leaders.

Annual General Meeting



June 7, 2023 at 4:00 PM ET

Following the completion of the Meeting, we’ll have a question and answer session. Please use the Audio Q&A link on your screen, under the Documents tab, to dial in and access the Q&A phone line. Once you are on the Q&A phone line, to ask a question during the session you will need to press Star One One on your telephone. You will then hear an automated message advising your hand is raised.

Annual General Meeting 2023 Presentation
Annual General Meeting Audio Replay
Management Information Circular


Investor Update

September 2023

Events & Webcasts

APAC 2023

Dr. Kellum presenting on numerous topics at The 5th Asia Pacific Acute Kidney Injury & Continuous Renal Replacement Therapy Congress (APAC) including Septic Shock and the Tigris Trial

September 21 – 24, 2023, Daegu, Korea

Endotoxic Septic Shock featured on The Balancing Act airing on Lifetime TV

Monday September 11 | 7:30am (ET/PT)

Sepsis Alliance Summit Sponsored Session: What is Endotoxin and Why is it Important?

Debra Foster, BSc

Wednesday September 27, 2023 | 1:40pm ET PST


Sepsis Alliance Sponsor Innovation Webinar: Precision Medicine for Sepsis: Targeted Therapy Based on Molecular Endotyping

Thursday September 30, 2021 @2:oopm EST / 11:00am PST

Watch the replay.

vicenza course 2022

40th Vicenza Course on Acute Kidney Injury (AKI) and Continuous Renal Replacement Therapy (CRRT) 

Endototoxemia in the Critically Ill and the Role of Polymyxin B Hemoperfusion

vicenza course 2021

39th Vicenza Course on Acute Kidney Injury (AKI) and Continuous Renal Replacement Therapy (CRRT) 

Meet the Expert:
Biomarkers (EAA) – Guided Initiation of PMX Hemoperfusion in Sepsis

Endotoxic Shock: From Pathophysiology to Advanced Targeted Solutions

Cappuccino with Claudio Ronco:
CRRT Technology Update

vicenza course 2020

38th Vicenza Course on Acute Kidney Injury (AKI) and Continuous Renal Replacement Therapy (CRRT) 

Cappuccino with Claudio Ronco

SAMI, an innovative platform for CRRT

Meet the Expert

Is Endotoxemia Relevant in COVID-19?


Web Symposium

Septic Shock and COVID-19: The Dysregulated Host Response

Meet the Expert

Endotoxemia and PMX therapy: a picture from the real clinical practice
Analyst Coverage


Scott McAuley, PhD – Analyst, Healthcare and Biotechnology
Tel: 416.361.9080
Please note that any opinions, estimates or forecasts regarding EDT’s performance made by the(se) analyst(s) is(are) theirs alone and do not represent opinions, forecasts or predictions of EDT or its management. EDT does not by its reference above or distribution imply any endorsement of or concurrence with such information, conclusions or recommendations.


Spectral is listed on the Toronto Stock Exchange under the symbol EDT.


Spectral’s regulatory filings on SEDAR


Find useful information regarding corporate governance at Spectral